Abstract: The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk of sustaining an adverse event.

Abstract: The present invention relates to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of (i) taking a sample of bodily fluid from said subject; (ii) determining in said sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; (iii) stratifying said subjects into either of the categories: (a) responder to a medication for treatment of said disease, (b) non-responder to a medication for treatment of said disease not showing an unfavourable effect after having received said medication; (c) subjects showing an unfavourable effect after having received said medication. The invention also relates to the use of an antibody or a functional fragment thereof in the method according to the invention.

Abstract: The present invention relates to a method for the diagnosis or prognosis of a disease or clinical condition in a subject comprising the steps of: (i) providing a sample of bodily fluid of a subject, (ii) determining the level of peroxiredoxin 4 (PRX4) or a fragment thereof having at least 20 amino acids residues in length in said sample, and (iii) correlating the level of PRX4 or a fragment thereof with a disease or clinical condition.

Abstract: The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections.

Abstract: The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.

Abstract: An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.

Abstract: The present invention relates to a diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic.

Abstract: The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis.

Abstract: The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases.

Abstract: The invention relates to an in vitro method for detecting the formation of endothelins during serious illnesses, especially cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient for medical diagnosis. Using this method, relatively long-lasting peptide fragments, especially a C-terminal peptide fragment, of the processed primary prepro- or proendothelins that contain neither the actual biologically active endothelin nor its direct precursor, big endothelin, can be detected.

Abstract: Subject of the present invention are assays and in vitro methods for the prediction of first coronary and cardiovascular events and biomarkers useful therein.

Abstract: Subject of the present invention are assays and in vitro methods for prediction of the progression of primary chronic kidney disease (CKD) or for monitoring chronic kidney disease therapy comprising the determination of the level of ANP and/or ADM or its precursors or fragments thereof.

Abstract: Subject of the present invention are assays and in vitro methods for the prediction of the risk of a subject for contracting metabolic syndrome and/or diabetes mellitus and for diagnosing metabolic syndrome, comprising determining the level of arginine vasopressin pro-hormone or fragments thereof in a sample of a subject.

Abstract: A nozzle arrangement (1) for detachable arrangement in an outlet of a tubular nozzle fitting, which is allocated to a high-pressure cleaning or conditioning device of a paper machine, having a rotationally-symmetric nozzle body (2), including a carrier (3) formed as a circular disk with a central recess (5) encompassed thereby and a dome (6) bulging with its wall over the recess (5) at a flat side (4) of the carrier (3), and with a first jet channel (7) penetrating the wall, in which at least one first nozzle element (8) is arranged, which forms the liquid passing the jet channel (7) into a laminar jet. The carrier (3) of the nozzle body (2) has an exterior contour with a constant curvature or one changing in reference to the rotational symmetry axis of the nozzle body (2).

Abstract: A nozzle arrangement (1) for a high-pressure cleaning or conditioning device of a paper machine having a nozzle body (2), with a first jet channel (3) for liquids impinged with high pressure passing therethrough, with at least one partially penetrating nozzle element (4) being arranged in the jet channel (3), which forms the liquid passing the jet channel (3) into a laminar jet (5). In order to provide a nozzle arrangement (1) increasing the efficiency of the spray tube with a good cleaning result and simultaneously reduced water consumption it is provided that at least one additional nozzle element (4) is located at the nozzle body, which is arranged in another jet channel (3) different from the first jet channel (3) or together with the first and/or another nozzle element (4) in a joint jet channel (3) and that the nozzle body (2) is arranged at the nozzle arrangement (1) rotational about its longitudinal axis without being off-set axially.

Abstract: The present invention is concerned with an assay for detecting and/or determining the level of a protease from azurophilic granules of polymorphonuclear neutrophils or a complex thereof with an endogenous inhibitor for risk stratification and/or prognosis and/or therapy control and/or monitoring of a patient having a cardiological disease or condition.

Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.

Abstract: Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction or risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject.

Abstract: Disclosed is an improved sandwich immunoassay for identifying partial proANP peptides in cardiac and sepsis diagnosis by using two antibodies which specifically bond to partial sequences in the mid-regional area of NT-proANP, extending from amino acid 53 to amino acid 83 of NT-proANP.

Abstract: The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases.